# Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

> **NCT01783730** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 163 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01783730
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01783730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01783730, "Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01783730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*